Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis.
Ophthalmology
; 125(12): 1977-1983, 2018 12.
Article
em En
| MEDLINE
| ID: mdl-30458922
ABSTRACT
The interleukin (IL)-23/IL-17 axis plays a central role in the pathogenesis of immune-mediated diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and uveitis. Therefore, targeting the IL-23/IL-17 axis has become the focus of multiple clinical trials for drug development in patients with autoimmune diseases. We briefly describe the biology of the IL-23/IL-17 axis and its relevance to the pathogenesis of experimental and clinical uveitis, and review the monoclonal antibody therapies targeting this pathway. Finally, 2 ongoing phase 2 trials of the anti-IL-23 biologic therapy ustekinumab (STELARA, Janssen Biotech Inc, Horsham, PA) in patients with noninfectious uveitis are introduced.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doenças Autoimunes
/
Uveíte
/
Terapia Biológica
/
Interleucina-23
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article